In yesterday’s Wall Street session, TC Biopharm (Holdings) Plc (NASDAQ:TCBP) shares traded at $4.00, up 8.40% from the previous session.
1 analysts cover TC Biopharm (Holdings) Plc (NASDAQ:TCBP), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $7.28 and a low of $7.28, we find $7.28. Given the previous closing price of $3.69, this indicates a potential upside of 97.29 percent. TCBP stock price is now -16.55% away from the 50-day moving average and -65.92% away from the 200-day moving average. The market capitalization of the company currently stands at $3.64M.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Sponsored
The stock has received a hold rating from 0 analysts and a buy rating from 1. Brokers who have rated the stock have averaged $7.28 as their price target over the next twelve months.
.
In other news, Randall Diana Elizabeth, 10% Owner bought 70,000 shares of the company’s stock on Nov 30. The stock was bought for $350,000 at an average price of $5.00. Upon completion of the transaction, the 10% Owner now directly owns 70,000 shares in the company, valued at $0.28 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 30, 10% Owner Randall Kenneth Edward bought 70,000 shares of the business’s stock. A total of $350,000 was incurred on buying the stock at an average price of $5.00. This leaves the insider owning 382,963 shares of the company worth $1.53 million. A total of 36.62% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in TCBP stock. A new stake in TC Biopharm (Holdings) Plc shares was purchased by ARMISTICE CAPITAL, LLC during the first quarter worth $331,000. UBS GROUP AG invested $6,000 in shares of TCBP during the first quarter. In total, there are 6 active investors with 12.40% ownership of the company’s stock.
On Thursday morning TC Biopharm (Holdings) Plc (NASDAQ: TCBP) stock kicked off with the opening price of $3.5400. During the past 12 months, TC Biopharm (Holdings) Plc has had a low of $2.81 and a high of $106.50. As of last week, the company has a debt-to-equity ratio of 3.33, a current ratio of 1.10, and a quick ratio of 1.10. The fifty day moving average price for TCBP is $4.7934 and a two-hundred day moving average price translates $11.7397 for the stock.
The latest earnings results from TC Biopharm (Holdings) Plc (NASDAQ: TCBP) was released for Jun, 2022.
TC Biopharm (Holdings) Plc(TCBP) Company Profile
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
